Quad Goals: Optimizing Efficacy, Safety, and Workflow in Newly Diagnosed Multiple Myeloma

This activity was originally presented at the 2026 HOPA Annual Conference in New Orleans, LA.

Approximately 36,000 individuals are newly diagnosed with multiple myeloma (MM) each year in the United States. Despite advances that have improved 5-year survival rates, the disease burden remains substantial, with patients facing multiple relapses and complex treatment pathways. This session addresses the role of oncology pharmacists in optimizing care for patients with newly diagnosed multiple myeloma (NDMM) through immune-based quadruplet regimens, practical integration of measurable residual disease (MRD) testing to guide treatment decisions, and proactive management of administration challenges and adverse effects. Expert presenters will explore how quadruplet combinations delivered through innovative methods have the potential to enhance patient experience, operational efficiency, and may achieve superior MRD-negativity rates and sustained survival outcomes. Participants will gain practical insights into selecting optimal quadruplet regimens based on patient-specific factors, implementing MRD testing protocols to inform maintenance therapy decisions, and establishing comprehensive supportive care strategies including infection prophylaxis and toxicity management. Through interactive case discussions, attendees will learn to navigate real-world implementation challenges, from workflow integration and staff training to patient counseling and reimbursement considerations, ultimately improving outcomes for patients with NDMM through enhanced care delivery.

Target audience: Oncology pharmacists

Type of activity: Application

Release date: April 15, 2026

Expiration date: April 15, 2027

Learner level: Advanced

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate efficacy, safety, and operational considerations of immune-based quadruplet regimens in newly diagnosed multiple myeloma (NDMM) to guide regimen selection and optimize implementation across diverse practice settings
• Apply minimal residual disease testing principles to support treatment planning for patients with NDMM
• Determine effective strategies to manage administration, adverse effects, and supportive care for NDMM regimens